The Centre will also launch a three-year-long anti-measles-rubella (MR) campaign next year at a cost of Rs 1,500 crore for saving children in the age group of nine months to 15 years from all kinds of measles.
Rotavirus is a common virus that causes diarrhoea among infants and children throughout the world. Presently, more that 1.50 lakh children die in the country due to the disease every year, of which rotavirus accounts to 50 per cent of the deaths.
"It will be a game changer in bringing down the child mortality as the new vaccine is expected to save more than 50,000 children per year," he said.
Diarrhoea also has high morbidity rate which will be controlled with the rotavirus dose.
"Apart from 1.50 children who die due to diarrhoea, at least two to three times of the children suffer from the disease. It not just the deaths that will be prevented but the whole gamut of diarrhoea-controlling exercise," he said.
Mishra said government is also geared up to launch the MR campaign by next year.
Through the campaign spread across three years, immunity will be developed among large number of children against measles as government plans to replace the current measles vaccine given under its immunisation programme with the combination of measles-rubella vaccine which poses danger of disease shifting from lower age group to higher age group.
"In the new vaccine, Rubella is getting added and measles will be phased out. But before that we will have to develop immunity of the larger cohort of nine months to 15 years. This will be done through the campaign. Once the campaign is over the current measles vaccines will be replaced by the combination of measles-rubella vaccine," Mishra said.
Another, Pneumococcal Conjugate Vaccine (PCV), which provides protection against pneumonia, will be inducted into the universal immunisation programme by 2017, Mishra said.
"This is also a huge effort for saving children from pneumonia. But for PCV, we will take a little time. We have got the approval but cannot be introduced before 2017," he said.
The government has also completed the introduction of pentavalent vaccine this month which started in December 2011 which prevents from five disease including diphteria, pertussis, tetanus, hepatitis and Haemophilus Influenzae Type- B (HIB) which causes pneumonia and meningitis, Mishra said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
